(MedPage Today) — The FDA granted accelerated approval to vusolimogene oderparepvec (Tudriqev), known as RP1, in combination with nivolumab (Opdivo) to treat adults with unresectable advanced cutaneous melanoma, the agency announced Thursday…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
